Vertex Pharmaceuticals

Vertex is a multinational biotechnology business that invests in scientific research to develop breakthrough treatments for patients suffering from serious and life-threatening diseases. It identified and developed the first treatments for cystic fibrosis (CF), a rare, life-threatening hereditary condition. Vertex has more than a dozen current research studies focused on the underlying mechanisms of other critical diseases, in addition to clinical development programs in CF.

Science Magazine, The Boston Globe, The Boston Business Journal, and the San Diego Business Journal have all named Vertex as one of the best places to work in the industry. Its research and treatments have also won prestigious prizes such as the Robert J. Beall Therapeutics Development Award, the French Prix Galien, and the British Pharmacological Society.

The mission is to improve the quality of life for those living with critical diseases through the research, development, and distribution of novel therapeutics. Vertex's research pipeline is extensive and includes potential game-changing treatments for a wide range of diseases and conditions, such as cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, Duchenne muscular dystrophy, type 1 diabetes, and more. Vertex prioritizes specialist markets and invests in cutting-edge research to develop game-changing treatments for life-threatening illnesses.

Founded: 1989
Headquarters: München, Germany
Website: https://www.vrtx.de/